astrazeneca - Search News

AstraZeneca, ENHERTU and Breast Cancer

AstraZeneca, Daiichi Sankyo Continue ADC Rally With Enhertu Expansion

Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast cancer.

Benzinga.com · 1d

FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients

FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant efficacy in the DESTINY-Breast06 trial.

MarketWatch · 2d

AstraZeneca Receives FDA Approval for Enhertu Breast Cancer Treatment

AstraZeneca received Food and Drug Administration approval for enhertu, its breast cancer treatment developed in partnership with Japanese company Daiichi Sankyo. The Anglo-Swedish pharmaceutical company said Monday that the treatment's approval was based on results from a Phase III trial,

Seeking Alpha on MSN · 2d

AstraZeneca's Enhertu gets additional FDA approval

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's (OTCPK:DSKYF) drug Enhertu has been approved by the FDA for the treatment of certain breast cancer patients. Enhertu was approved for the treatment of unresectable or metastatic HR-positive,

7hon MSN

AstraZeneca's SWOT analysis: pharma giant's stock poised for growth amid challenges

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

Zacks.com on MSN16h

Should AstraZeneca Stock Be in Your Portfolio Pre-Q4 Earnings?

AstraZeneca AZN will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus ...

AstraZeneca rises Monday, outperforms market

Shares of AstraZeneca PLC AZN rallied 1.18% to £111.80 Monday, on what proved to be an all-around positive trading session ...

AstraZeneca To Pump $570 Million Into Canada, Driving Expansion, Job Growth

AstraZeneca invests $570 million in Canada, expands facilities, and boosts R&D efforts, aiming to deliver 20 new medicines ...

13d

Harnessing AI and data science to discover life-changing medicines at AstraZeneca

From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...

AstraZeneca's Growth Potential: 6 Reasons For A Buy Rating

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

News Medical on MSN8d

AstraZeneca's Pioneering Research in Heart Failure and ATTR-CM

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...

Business Facilities5d

AstraZeneca Will Invest $820M In Ontario R&D Hub

AstraZeneca will expand the its global R&D hub in Mississauga. This $820 million investment underscores Ontario ’s growing ...

Berenberg Bank Keeps Their Buy Rating on AstraZeneca (AZN)

In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price ...

AstraZeneca PLC ADR rises Monday, outperforms market

The AstraZeneca PLC ADR AZN rallied 1.48% to $70.08 Monday, on what proved to be an all-around mixed trading session for the ...

‘I was desperate for the AstraZeneca vaccine to succeed. Then I became alarmed by what I saw’

Haematologist Dr Sue Pavord was one of the jab’s biggest supporters, but she knew something was wrong when she saw the ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

AstraZeneca, ENHERTU and Breast Cancer

Related topics